Citigroup reiterates KOS at hold

KOS Pharmaceuticals Inc. was reiterated at a hold rating by Citigroup Investment Research analyst Andrew Swanson. The company will report its fourth-quarter 2005 results before the market opens on Thursday. Citigroup forecasts earnings of $0.81 per share, down 35% versus the fourth quarter of 2004, and one cent ahead of the consensus expectation of $0.80. The analyst sees the cholesterol franchise as the dominant driver and forecast franchise (Niaspan and Advicor) sales of $156 million. Shares of the Cranbury, N.J., pharmaceutical company were up 84 cents, or 1.72%, at $49.77 on volume of 550,340 shares versus the three-month running average of 793,531 shares. (Nasdaq: KOSP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.